Current efforts to improve diversity in clinical research fall short for the LGTBQIA+ population.
In this webinar, expert panelists discussed how sponsors can smooth the LGBTQIA+ patient journey for clinical trials, starting with gender-neutral protocols, making trial communication more inclusive, the FDA’s draft guidance on diversity plans and data collection, and the roles that sites/investigators can play.
Upon completion of this continuing education program, participants should be able to:
Know the basics — and limitations — of the FDA’s diversity plan requirements
Understand the importance of including LGBTQIA+ trial participants
Discover ways technology can capture SOGI (sexual orientation and gender identity) data
Speakers:
Fenwick Eckhardt (she/her), Head of Diversity Strategy, Citeline
Liam Paschall (he/him), Founder and Director of Liam Paschall Consulting and Global Enablement Manager, Global Sales Onboarding at Adobe
Shir Netanel (she/her), Associate Director, Patient Advocacy and Clinical Trial Advocacy, Global Medical Affairs Oncology, Johnson & Johnson
Garo Kiledjian (he/him), Founder and CEO, SGM Alliance